Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool, NHS Chair of Pharmacogenetics and Chair of the Prix Galien UK Committee, said: 'This year's submissions were of exceptional caliber, making the task of selecting winners both challenging and inspiring. The awardees have demonstrated groundbreaking progress in their fields, and their work holds great promise for patients worldwide.'
Bruno Cohen, Chairman of The Galien Foundation, said: 'The Prix Galien UK continues to reflect the extraordinary scientific talent and commitment within the United Kingdom's life sciences sector. The 2025 winners exemplify the power of innovation to transform patient care and represent a pioneering group shaping the future of healthcare. We are proud to celebrate these remarkable contributions, which reinforce the UK's leading role in advancing global health.'
The development and implementation of R21/Matrix-M was the result of a tremendous collaborative effort between the Jenner Institute, University of Oxford, Serum Institute of India Pvt. Ltd. and all the sites involved in the clinical trials; IRSS Burkina Faso, Malaria Research and Training Center/USTTB /Laboratory of Malaria Immunology and Vaccinology, KEMRI - Wellcome Trust, Institut des Sciences et Techniques (INSTech), Bobo-Dioulasso, Burkina Faso and Ifakara Health Research Institute.
As of April 2025, R21/Matrix-M has been distributed in 12 malaria-endemic countries, where it will be instrumental in the fight against Malaria.
Read the story on the Nuffield Department of Medicine website.